Mission Therapeutics

Mission Therapeutics is a UK-based drug discovery and development company located in Cambridge. The company specializes in creating first-in-class small-molecule inhibitors that target deubiquitylating enzymes (DUBs) to address serious diseases with high unmet needs, including Parkinson’s Disease, Alzheimer’s Disease, and acute kidney injury. Founded as a leader in DUB-targeted therapies, Mission Therapeutics utilizes a proprietary platform to develop innovative drugs that enhance cellular health by promoting mitophagy. The company’s pipeline includes key assets like MTX325, a USP30 inhibitor in Phase II clinical trials for Parkinson’s Disease, and MTX652, which is also in Phase II for Acute Kidney Injury. Mission collaborates with major pharmaceutical companies, such as AbbVie and Pfizer, to validate and develop its DUB inhibitors, while maintaining partnerships with academic and research institutions to support its scientific endeavors. The company has successfully raised £117 million from a network of institutional and corporate investors, which supports its ongoing research and development efforts.